嗜酸性粒细胞食管炎治疗目标的转变

IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Katrina Ray
{"title":"嗜酸性粒细胞食管炎治疗目标的转变","authors":"Katrina Ray","doi":"10.1038/s41575-024-00969-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"21 9","pages":"605-605"},"PeriodicalIF":45.9000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Shifting targets for eosinophilic oesophagitis\",\"authors\":\"Katrina Ray\",\"doi\":\"10.1038/s41575-024-00969-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18793,\"journal\":{\"name\":\"Nature Reviews Gastroenterology &Hepatology\",\"volume\":\"21 9\",\"pages\":\"605-605\"},\"PeriodicalIF\":45.9000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Gastroenterology &Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41575-024-00969-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41575-024-00969-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

新英格兰医学杂志》报道了两项治疗嗜酸性粒细胞性食管炎(EoE)新药的III期试验。在第一项试验(EoE KIDS)中,Mirna Chehade及其同事评估了dupilumab(一种阻断IL-4和IL-13通路的人类单克隆抗体)对1-11岁食管炎患者的治疗效果。"杜匹鲁单抗于2022年5月在美国获批用于治疗12岁及以上的儿童咽喉炎患者。随后,2024 年 1 月,FDA 又将批准范围扩大到治疗 1 岁及以上、体重至少 15 千克的儿童,"Chehade 解释说,他补充说,这些新结果为 FDA 最近的批准提供了依据。在这项 III 期试验中,患有活动性咽喉炎的儿童患者(n = 102;平均年龄 7.1岁;76%为男孩,24%为女孩),按2:2:1:1的比例随机分配,接受体重分层的高暴露剂量的dupilumab、低暴露剂量的dupilumab或安慰剂治疗16周(A部分),随后是为期36周的延长期积极治疗阶段,在这一阶段中,每个dupilumab组中符合条件的患者继续采用相同的治疗方案,而安慰剂组中的患者则被分配到低暴露剂量或高暴露剂量的dupilumab(B部分)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Shifting targets for eosinophilic oesophagitis

Shifting targets for eosinophilic oesophagitis
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
52.30
自引率
0.60%
发文量
147
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信